Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 28 peer-reviewed journal articles Updated
Neurology

Understanding Narcolepsy Type 1

At a Glance

Narcolepsy Type 1 is a chronic neurological disorder caused by an autoimmune response that destroys brain cells producing hypocretin (orexin). This permanent loss disrupts sleep-wake cycles, leading to severe daytime sleepiness and cataplexy, which are manageable with treatment.

Receiving a diagnosis of Narcolepsy Type 1 (NT1) can feel like finally finding a name for a long-standing shadow. For many, this moment brings a complicated mix of relief that their struggles are valid and grief for the years spent searching for answers [1][2]. It is normal to feel overwhelmed or anxious about what a lifelong condition means for your future [3][4]. Understanding the science of what is happening in your brain is the first step toward regaining a sense of control.

Three Stabilizing Facts

When first diagnosed, it is helpful to ground yourself in these three core realities:

  1. It is a physical, biological condition: NT1 is not caused by “laziness,” lack of willpower, or poor sleep habits [5]. It is a neurological disorder rooted in the loss of specific brain cells [3].
  2. Symptoms are manageable: While there is currently no cure, many effective treatments exist to help manage sleepiness and cataplexy (sudden muscle weakness triggered by emotions) [6][7].
  3. You are not alone: NT1 is a recognized medical condition with a dedicated community of patients and specialists. Connecting with others who share the diagnosis is one of the strongest predictors of feeling supported [8].

Type 1 vs. Type 2 Narcolepsy

To understand NT1, it helps to know that there is also a Narcolepsy Type 2 (NT2). While both cause severe daytime sleepiness, NT1 involves the specific loss of a brain chemical called hypocretin and the presence of cataplexy [9]. NT2 does not involve a hypocretin deficiency, and people with NT2 do not experience cataplexy [10].

The Role of Hypocretin (Orexin)

At the heart of NT1 is the loss of a vital chemical messenger in the brain called hypocretin (also known as orexin) [11]. Under normal conditions, specialized neurons in a region of the brain called the hypothalamus produce hypocretin to act as a “master switch” for wakefulness [5].

Hypocretin has two primary jobs:

  • Stabilizing Wakefulness: It provides a steady signal that keeps you awake and alert during the day [12]. Without it, the “switch” between being awake and asleep becomes unstable, leading to excessive daytime sleepiness (EDS) [5][13].
  • Regulating REM Sleep: It prevents Rapid Eye Movement (REM) sleep—the stage of sleep where dreaming and muscle paralysis occur—from “leaking” into your waking hours [14].

In people with NT1, these hypocretin-producing neurons are nearly entirely absent [3]. This loss is what causes the hallmark symptoms of narcolepsy, including the sudden muscle weakness of cataplexy, which is essentially REM-related muscle paralysis occurring while you are still awake [15][16].

An Autoimmune Connection

Current medical research identifies NT1 as an autoimmune-mediated disorder [3][17]. In an autoimmune response, the body’s immune system mistakenly identifies its own healthy cells as foreign invaders and attacks them. In the case of NT1, the immune system specifically targets and destroys the hypocretin-producing neurons in the hypothalamus [11][18].

Scientists have identified several factors that contribute to this process:

  • Genetic Susceptibility: Most people with NT1 carry a specific genetic marker known as HLA-DQB1*06:02 [19][20]. While many people have this marker and never develop narcolepsy, it appears to be a necessary “key” that allows the immune system to misidentify hypocretin cells [21][22].
  • Environmental Triggers: It is believed that certain triggers, such as an infection (like the flu), may cause the immune system to become confused—a process called molecular mimicry [11][23]. The immune system attacks the infection, but because the infection looks similar to hypocretin cells, it destroys those neurons as well [24].
  • Note on Triggers: These infections act as the initial trigger for the onset of the disease, often occurring in childhood or adolescence [25]. Because the loss of these neurons is a one-time event, catching the flu or another infection after the narcolepsy has developed will not worsen your baseline condition [23].

Looking Ahead

Because the loss of hypocretin neurons is permanent, NT1 is a chronic, lifelong condition [3][10]. However, understanding that your brain has lost its “stability switch” allows you and your care team to use targeted strategies to mimic that stability through medication and lifestyle adjustments [26][27]. Your diagnosis is not a boundary on what you can achieve, but rather a new map for how to navigate your energy and health [28].

Common questions in this guide

What is the difference between Narcolepsy Type 1 and Type 2?
The main difference is that Narcolepsy Type 1 involves a loss of the brain chemical hypocretin and includes cataplexy, which is sudden muscle weakness. People with Narcolepsy Type 2 have normal hypocretin levels and do not experience cataplexy.
What causes Narcolepsy Type 1?
Narcolepsy Type 1 is considered an autoimmune disorder. The body's immune system mistakenly attacks and destroys the specific brain cells in the hypothalamus that produce hypocretin, the chemical responsible for regulating wakefulness.
What is cataplexy?
Cataplexy is sudden muscle weakness triggered by strong emotions, such as laughter, surprise, or anger. In Narcolepsy Type 1, this happens because the muscle paralysis normally reserved for REM sleep mistakenly occurs while you are awake.
Can a viral infection cause narcolepsy?
Yes, certain environmental triggers like the flu can cause the onset of the disease in people with a specific genetic marker. The immune system attacks the infection but may become confused and mistakenly destroy healthy hypocretin cells at the same time.
Is there a cure for Narcolepsy Type 1?
Because the loss of hypocretin-producing neurons is permanent, there is currently no cure for the condition. However, symptoms like excessive daytime sleepiness and cataplexy can be effectively managed with targeted medications and lifestyle adjustments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and testing, is it confirmed that I have a deficiency in hypocretin (orexin)?
  2. 2.How does the autoimmune nature of this condition affect my long-term health or risk for other conditions?
  3. 3.What is the specific goal of my initial treatment plan—reducing daytime sleepiness, managing cataplexy, or both?
  4. 4.Are there lifestyle adjustments, such as scheduled naps or dietary changes, that you recommend alongside medication?
  5. 5.Can you explain my sleep study results in the context of my NT1 diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (28)
  1. 1

    Diagnostic delay in narcolepsy type 1: combining the patients' and the doctors' perspectives.

    Taddei RN, Werth E, Poryazova R, et al.

    Journal of sleep research 2016; (25(6)):709-715 doi:10.1111/jsr.12420.

    PMID: 27149919
  2. 2

    Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years.

    Zhang Z, Barateau L, Béziat S, et al.

    Journal of sleep research 2026; (35(2)):e70170 doi:10.1111/jsr.70170.

    PMID: 40817031
  3. 3

    Narcolepsy and Idiopathic Hypersomnia.

    Blattner M, Maski K

    Sleep medicine clinics 2023; (18(2)):183-199 doi:10.1016/j.jsmc.2023.01.003.

    PMID: 37120161
  4. 4

    Dissociative episode and panic attacks triggered by pitolisant in a narcoleptic patient.

    Brunetti V, Marotta J, Simoncini Malucelli G, et al.

    International clinical psychopharmacology 2023; (38(2)):114-116 doi:10.1097/YIC.0000000000000430.

    PMID: 36165509
  5. 5

    Orexin neurons inhibit sleep to promote arousal.

    De Luca R, Nardone S, Grace KP, et al.

    Nature communications 2022; (13(1)):4163 doi:10.1038/s41467-022-31591-y.

    PMID: 35851580
  6. 6

    Interim analysis of a post-authorization safety study of pitolisant in treating narcolepsy: A real-world European study.

    Plazzi G, Mayer G, Bodenschatz R, et al.

    Sleep medicine 2025; (129()):20-30 doi:10.1016/j.sleep.2025.02.012.

    PMID: 39978240
  7. 7

    Armodafinil as Monotherapy in Treating Narcolepsy with Cataplexy.

    Ahmed A, Tariq S, Khan SJ, Shah ZH

    Cureus 2024; (16(12)):e76437 doi:10.7759/cureus.76437.

    PMID: 39737109
  8. 8

    Social support and isolation in narcolepsy and idiopathic hypersomnia: An international survey.

    Flygare J, Oglesby L, Parthasarathy S, et al.

    Sleep medicine 2025; (125()):65-73 doi:10.1016/j.sleep.2024.11.013.

    PMID: 39561673
  9. 9

    A rare genetic variant in the cleavage site of prepro-orexin is associated with idiopathic hypersomnia.

    Miyagawa T, Tanaka S, Shimada M, et al.

    NPJ genomic medicine 2022; (7(1)):29 doi:10.1038/s41525-022-00298-w.

    PMID: 35414074
  10. 10

    Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers.

    Rauf R, Asif S, AlSaafeen A, et al.

    Brain and behavior 2025; (15(10)):e70984 doi:10.1002/brb3.70984.

    PMID: 41076550
  11. 11

    Research Progress in the Roles of Influenza A H1N1 Virus and Its Vaccine in the Pathogenesis of Narcolepsy Type 1.

    Ding WT, Gao JY, Guo ZL, et al.

    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2025; (47(6)):997-1005 doi:10.3881/j.issn.1000-503X.16463.

    PMID: 41503654
  12. 12

    Cortical arousal frequency is increased in narcolepsy type 1.

    Brink-Kjaer A, Christensen JAE, Cesari M, et al.

    Sleep 2021; (44(5)) doi:10.1093/sleep/zsaa255.

    PMID: 33249455
  13. 13

    Dissociating orexin-dependent and -independent functions of orexin neurons using novel Orexin-Flp knock-in mice.

    Chowdhury S, Hung CJ, Izawa S, et al.

    eLife 2019; (8()).

    PMID: 31159922
  14. 14

    Deficiency of orexin signaling during sleep is involved in abnormal REM sleep architecture in narcolepsy.

    Ito H, Fukatsu N, Rahaman SM, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2023; (120(41)):e2301951120 doi:10.1073/pnas.2301951120.

    PMID: 37796986
  15. 15

    Serotonin neurons in the dorsal raphe mediate the anticataplectic action of orexin neurons by reducing amygdala activity.

    Hasegawa E, Maejima T, Yoshida T, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2017; (114(17)):E3526-E3535 doi:10.1073/pnas.1614552114.

    PMID: 28396432
  16. 16

    Activity of putative orexin neurons during cataplexy.

    Zhou S, Yamashita A, Su J, et al.

    Molecular brain 2022; (15(1)):21 doi:10.1186/s13041-022-00907-w.

    PMID: 35246205
  17. 17

    The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.

    Xu W, Ding W, Zhang Y, et al.

    International journal of molecular sciences 2024; (25(22)) doi:10.3390/ijms252211914.

    PMID: 39595997
  18. 18

    Increased neutrophil-to-lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.

    Conti M, Cirillo F, Maio S, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(1)):101-107 doi:10.5664/jcsm.11368.

    PMID: 39297540
  19. 19

    Correlation between HLA-DQB1*06:02 and narcolepsy with and without cataplexy: approving a safe and sensitive genetic test in four major ethnic groups. A systematic meta-analysis.

    Capittini C, De Silvestri A, Terzaghi M, et al.

    Sleep medicine 2018; (52()):150-157 doi:10.1016/j.sleep.2018.08.024.

    PMID: 30321823
  20. 20

    Narcolepsy type I-associated DNA methylation and gene expression changes in the human leukocyte antigen region.

    Yoshida-Tanaka K, Shimada M, Honda Y, et al.

    Scientific reports 2023; (13(1)):10464 doi:10.1038/s41598-023-37511-4.

    PMID: 37380713
  21. 21

    CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens.

    Pedersen NW, Holm A, Kristensen NP, et al.

    Nature communications 2019; (10(1)):837 doi:10.1038/s41467-019-08774-1.

    PMID: 30783092
  22. 22

    Association between human leukocyte antigen class II-DR-DQ and narcolepsy: a case control study.

    Bacelar A, Fernandez O, Paradella E, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2024; (20(12)):1945-1953 doi:10.5664/jcsm.11300.

    PMID: 39150697
  23. 23

    What triggered narcolepsy: H1N1 vaccination, virus, or both? Important lessons learned from China.

    Gool JK, Schinkelshoek MS, Fronczek R

    Sleep 2023; (46(3)) doi:10.1093/sleep/zsad005.

    PMID: 36629301
  24. 24

    Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells.

    Lecendreux M, Churlaud G, Pitoiset F, et al.

    PloS one 2017; (12(1)):e0169836 doi:10.1371/journal.pone.0169836.

    PMID: 28107375
  25. 25

    Microstructural White Matter Abnormalities in Children and Adolescents With Narcolepsy Type 1.

    Hovi M, Roine U, Autti T, et al.

    Pediatric neurology 2024; (153()):56-64 doi:10.1016/j.pediatrneurol.2024.01.015.

    PMID: 38320459
  26. 26

    Repeated measures of hypocretin-1 in Danish and Italian patients with narcolepsy and in controls.

    Torstensen EW, Haubjerg Østerby NC, Pizza F, et al.

    Sleep medicine 2023; (101()):213-220 doi:10.1016/j.sleep.2022.10.004.

    PMID: 36427467
  27. 27

    Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice.

    Drakatos P, Lykouras D, D'Ancona G, et al.

    Sleep medicine 2017; (35()):80-84 doi:10.1016/j.sleep.2017.03.028.

    PMID: 28619187
  28. 28

    Effort/reward imbalance and comorbidities burden in academic and professional careers of patients with narcolepsy type 1.

    Peter-Derex L, Fort E, Putois B, et al.

    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2025; (21(6)):983-997 doi:10.5664/jcsm.11598.

    PMID: 39943847

This page is for educational and informational purposes only and does not replace professional medical advice. Always consult your sleep specialist or healthcare provider regarding your Narcolepsy Type 1 diagnosis and treatment plan.

Get notified when new evidence is published on Narcolepsy type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.